81 results
8-K
EX-99.1
AKRO
Akero Therapeutics Inc
10 May 24
Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
7:17am
and injury to liver cells, leading to inflammation and fibrosis, which can progress to cirrhosis, liver failure, cancer and eventually death. MASH
424B5
AKRO
Akero Therapeutics Inc
6 Mar 24
Prospectus supplement for primary offering
5:16pm
(%)
13 (68%***)
p<0.001, versus placebo (CMH)
Summary of Week 96 Changes in Key Noninvasive Measures of Liver Fibrosis and Injury
Measure
(LS Mean
424B5
AKRO
Akero Therapeutics Inc
4 Mar 24
Prospectus supplement for primary offering
5:21pm
;0.001, versus placebo (CMH)
Summary of Week 96 Changes in Key Noninvasive Measures of Liver Fibrosis and Injury
Measure
(LS Mean Change From
8-K
EX-99.2
AKRO
Akero Therapeutics Inc
4 Mar 24
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
7:55am
, no imputation) 15
Statistically Significant Improvements in Markers of Liver Injury Sustained Through Week 96 ALT AST LS Mean Percent Change from Baseline LS
8-K
EX-99.1
7fqe8 io6i7ex38mm5k
4 Mar 24
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
7:55am
8-K
EX-99.1
cceb eonl4azquyjqsv
29 Feb 24
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7:15am
8-K
EX-99.1
0frahpq0 qqk
18 Dec 23
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
7:08am
8-K
EX-99.1
wo79d1wxsmhpfkiv8
13 Nov 23
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:15am
8-K
EX-99.2
kxh9nshzt5rxudt
10 Oct 23
Regulation FD Disclosure
8:04am
8-K
wh6gt1rhfk2
10 Oct 23
Regulation FD Disclosure
8:04am
8-K
EX-99.1
u04j5s
10 Oct 23
Regulation FD Disclosure
8:04am
8-K
EX-99.1
tc7rk3v
11 Aug 23
Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
6:09am
8-K
EX-99.2
wntna sqhnlrtst4caq
5 Jun 23
Results of Operations and Financial Condition
8:05am
8-K
EX-99.1
f3nl4ie7fg
5 Jun 23
Results of Operations and Financial Condition
8:05am
8-K
EX-99.1
hkf2dyl1lvgm856jt3ov
15 May 23
Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
7:19am